• Hélène Jakobczyk, Flavien Sciortino, Soizic Chevance, Fabienne Gauffre, and Marie-Bérengère Troadec.
• Institut de Génétique et Développement de Rennes, UMR 6290 CNRS, Université de Rennes 1, Rennes, France; SFR Biosit UMS CNRS 3480/US INSERM 018, Rennes, France. Electronic address: helene.jakobczyk@univ-rennes1.fr.
• Int J Pharm. 2017 Nov 5; 532 (2): 813-824.

AbstractA number of nanoparticles has been developed by chemists for biomedical applications to meet imaging and targeting needs. In parallel, adoptive T therapy with chimeric antigen receptor engineered T cells (CART cells) has recently held great promise in B-cell malignancy treatments thanks to the development of anti-CD19 CAR T cells. Indeed, CD19 is a reliable B cell marker and a validated target protein for therapy. In this perspective article, we propose to discuss the advantages, limits and challenges of nanoparticles and CAR T cells, focusing on CD19 targeting objects: anti-CD19 nanoparticles and anti-CD19 CAR T cells, because those genetically-modified cells are the most widely developed in clinical setting. In the first part, we will introduce B cell malignancies and the CD19 surface marker. Then we will present the positioning of nanomedicine in the topic of B cell malignancy, before exposing CAR T technology. Finally, we will discuss the complementary approaches between nanoparticles and CAR T cells.Copyright © 2017 Elsevier B.V. All rights reserved.

24 keywords...

hide…